ALD R491
Alternative Names: ALD-R491; R491Latest Information Update: 19 Oct 2021
At a glance
- Originator Aluda Pharmaceuticals
- Class Anti-inflammatories; Antifibrotics; Antineoplastics; Antivirals; Exosome therapies; Small molecules
- Mechanism of Action Vimentin inhibitors; Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Cancer; COVID 2019 infections; Encephalitis; Hepatic fibrosis; Idiopathic pulmonary fibrosis; Inflammatory bowel diseases
Most Recent Events
- 13 Oct 2021 Pharmacodynamics data from a preclinical study in COVID-2019 infections released by Aluda Pharmaceuticals
- 20 Jul 2021 Aluda Pharmaceuticals plans phase I trials for ALD R491 (Aluda Pharmaceuticals, July 2021)
- 20 Jul 2021 ALD R491 is available for licensing as of 20 Jul 2021 (Aluda Pharmaceuticals July 2021)